430.29

1.44% -6.66

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$436.95

Offen:

$433.96

24-Stunden-Volumen:

212.42K

Relative Volume:

0.57

Marktkapitalisierung:

$9.55B

Einnahmen:

Nettoeinkommen (Verlust:

$-518.67M

KGV:

-17.13

EPS:

-25.12

Netto-Cashflow:

$-438.32M

1W Leistung:

-4.22%

1M Leistung:

-4.02%

6M Leistung:

+37.18%

1J Leistung:

+104.23%

1-Tages-Spanne:

$425.60

$443.60

1-Wochen-Bereich:

$425.60

$453.58

52-Wochen-Spanne:

$200.63

$463.62

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1147)

Branche

Biotechnology (639)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

528

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Vergleichen Sie MDGL mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL Madrigal Pharmaceuticals Inc	430.20	9.74B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	415.33	107.98B	11.39B	3.64B	3.50B	13.99
ALNY Alnylam Pharmaceuticals Inc	454.88	59.07B	2.46B	-319.09M	-52.09M	-2.4669
REGN Regeneron Pharmaceuticals Inc	566.01	59.76B	14.21B	4.46B	3.56B	39.69
ARGX Argen X Se Adr	803.47	49.19B	3.06B	1.28B	447.35M	19.67
ONC Beone Medicines Ltd Adr	335.20	38.56B	4.56B	-176.77M	225.30M	-1.7177

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-02-28	Hochstufung	B. Riley Securities	Neutral → Buy
2025-02-27	Bestätigt	H.C. Wainwright	Buy
2024-06-28	Eingeleitet	Cantor Fitzgerald	Neutral
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-04-22	Eingeleitet	BofA Securities	Underperform
2024-03-15	Hochstufung	B. Riley Securities	Sell → Neutral
2024-03-06	Eingeleitet	Citigroup	Buy
2024-02-26	Herabstufung	B. Riley Securities	Neutral → Sell
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

06:29 AM

Market reaction to Madrigal Pharmaceuticals Inc.’s recent news2025 Fundamental Recap & Weekly Momentum Stock Picks - newser.com

06:29 AM

06:19 AM

Live market analysis of Madrigal Pharmaceuticals Inc.July 2025 Review & Entry Point Confirmation Alerts - newser.com

06:19 AM

03:49 AM

Madrigal Pharmaceuticals Inc. stock daily chart insights2025 Top Decliners & Technical Entry and Exit Alerts - newser.com

03:49 AM

03:01 AM

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

03:01 AM

Oct 08, 2025

What analysts say about Madrigal Pharmaceuticals Inc YDO1 stockSector Leadership Analysis & Exceptional Growth Portfolio - earlytimes.in

Oct 08, 2025

Oct 07, 2025

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Oct 07, 2025

Knights of Columbus Asset Advisors LLC Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Oct 07, 2025

Oct 06, 2025

How strong is Madrigal Pharmaceuticals Inc. (YDO1) stock earnings growthTrade Analysis Report & Fast Moving Stock Trade Plans - newser.com

Oct 06, 2025

Short interest data insights for Madrigal Pharmaceuticals Inc.Quarterly Profit Summary & AI Enhanced Trading Signals - newser.com

Oct 06, 2025

Will Madrigal Pharmaceuticals Inc. (YDO1) stock keep high P E multiplesJuly 2025 Rallies & Long-Term Investment Growth Plans - newser.com

Oct 06, 2025

Oct 05, 2025

Strid Group LLC Buys Shares of 2,500 Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Oct 05, 2025

Published on: 2025-10-05 03:01:06 - newser.com

Oct 05, 2025

Oct 04, 2025

J. Safra Sarasin Holding AG Increases Holdings in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat

Oct 04, 2025

Oct 03, 2025

Madrigal Pharmaceuticals Hits New 52-Week High of $463.48 - Markets Mojo

Oct 03, 2025

Signal strength of Madrigal Pharmaceuticals Inc. stock in tech scannersJuly 2025 Opening Moves & Low Risk Investment Opportunities - newser.com

Oct 03, 2025

Q3 Earnings Estimate for MDGL Issued By B. Riley - Defense World

Oct 03, 2025

Oct 02, 2025

How to use Fibonacci retracement on Madrigal Pharmaceuticals Inc.Earnings Overview Report & Technical Pattern Based Signals - newser.com

Oct 02, 2025

What is B. Riley's Forecast for MDGL Q3 Earnings? - MarketBeat

Oct 02, 2025